Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Metabolically-resistant synthetic bioisostere overlaid on natural 5-InsP7  (left) and its co-crystal structure (right)
Metabolically-resistant synthetic bioisostere overlaid on natural 5-InsP7 (left) and its co-crystal structure (right)

Structural snapshots of protein/ligand complexes are crucial to gain insight into enzymatic reaction mechanisms. Diphospho-myo-inositol polyphosphates such as 5-InsP7 regulate immunity and phosphate homeostasis and are phosphatase substrates.

Data from a tripartite collaboration, between the Potter group within Oxford Pharmacology, the NIH and Freiburg University, “A structural exposé of noncanonical molecular reactivity within the protein tyrosine phosphatase WPD loop” just published in Nature Communications include the first multiple substrate/enzyme crystal complexes from a variety of pre-reactant-, reactant-, intermediate- and product-bound states for a Cys-based Arabidopsis thaliana protein tyrosine phosphate-phosphatase lacking a functional canonical catalytic acid.

These provide the first data-driven mechanism for a reaction cycle that does not utilize any amino-acid residue as a general acid, showing how the enzyme is optimized for regiospecific and rapid hydrolysis of the β-phosphate of its pyrophosphate substrate and how the latter can drive its own hydrolysis.

The work used a metabolically-resistant synthetic 5-InsP7 bioisostere (pink ligand), designed in the Potter group that replaces the scissile 5-β-phosphate of 5-InsP7 (grey) with a phosphonodifluoromethyl group. The co-crystallized ligand orientates like 5-InsP7 but with a gain-of-function interaction between one fluorine atom and a guanidinium group. Very notably the work also identifies crystallographically a highly elusive and reactive metaphosphate-like intermediate in the reaction cycle.

Read the paper:

Similar stories

Fran Platt awarded 2023 Thudichum Medal

Pharmacology Head of Department, Professor Fran Platt, has been announced as the winner of the 2023 Thudichum Medal, presented by the Biochemical Society.

Join Pharmacology as the next Blaschko Fellow

Two year fellowship, offered in association with Linacre College, which offers full salary support, funding for travel and consumables and college accommodation. Join one of the existing groups in Pharmacology and develop your own research programme.

Sir Jon Symonds joins Pharmacology as a Visiting Fellow

The Department of Pharmacology is delighted to announce the appointment of Sir Jonathan Symonds CBE, Chair of the Board of GlaxoSmithKline, as a Visiting Fellow. Jon has been Chairman of the Board at GSK since September 2019.

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

New insight into the pharmacology of a therapeutic ion channel target

A new paper, published by the Tammaro lab in the Proceedings of the National Academy of Sciences (PNAS), shines new light on potential sites for pharmacological intervention within TMEM16A channels.